Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Vaccine Technologies Market

ID: MRFR/Pharma/14130-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

US Vaccine Technologies Market Research Report By Type (Recombinant, Conjugate, Subunit, Inactivated, Live Attenuated, Toxoid), By Route of Administration (Parenteral, Oral), By Disease Indication (Viral Diseases, Bacterial Diseases), By Age Group (Pediatric, Adults) and By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Vaccine Technologies Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Type (USD Billion)
  49.     4.1.1 Recombinant/Conjugate/Subunit
  50.     4.1.2 Inactivated
  51.     4.1.3 Live Attenuated
  52.     4.1.4 Toxoid
  53.   4.2 Life Sciences, BY Route of Administration (USD Billion)
  54.     4.2.1 Parenteral
  55.     4.2.2 Oral
  56.   4.3 Life Sciences, BY Disease Indication (USD Billion)
  57.     4.3.1 Viral Diseases
  58.     4.3.2 Bacterial Diseases
  59.   4.4 Life Sciences, BY Age Group (USD Billion)
  60.     4.4.1 Pediatric
  61.     4.4.2 Adults
  62.   4.5 Life Sciences, BY Distribution Channel (USD Billion)
  63.     4.5.1 Hospital & Retail Pharmacies
  64.     4.5.2 Government Suppliers
  65.     4.5.3 Others
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Life Sciences
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Pfizer (US)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Moderna (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 AstraZeneca (GB)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Johnson & Johnson (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 Sanofi (FR)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 GSK (GB)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Novavax (US)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 Merck (US)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.     5.2.9 Bharat Biotech (IN)
  131.       5.2.9.1 Financial Overview
  132.       5.2.9.2 Products Offered
  133.       5.2.9.3 Key Developments
  134.       5.2.9.4 SWOT Analysis
  135.       5.2.9.5 Key Strategies
  136.     5.2.10 Sinovac Biotech (CN)
  137.       5.2.10.1 Financial Overview
  138.       5.2.10.2 Products Offered
  139.       5.2.10.3 Key Developments
  140.       5.2.10.4 SWOT Analysis
  141.       5.2.10.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 US MARKET ANALYSIS BY TYPE
  148.   6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  149.   6.4 US MARKET ANALYSIS BY DISEASE INDICATION
  150.   6.5 US MARKET ANALYSIS BY AGE GROUP
  151.   6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  152.   6.7 KEY BUYING CRITERIA OF LIFE SCIENCES
  153.   6.8 RESEARCH PROCESS OF MRFR
  154.   6.9 DRO ANALYSIS OF LIFE SCIENCES
  155.   6.10 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  156.   6.11 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  157.   6.12 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  158.   6.13 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
  159.   6.14 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
  160.   6.15 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  161.   6.16 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  162.   6.17 LIFE SCIENCES, BY DISEASE INDICATION, 2024 (% SHARE)
  163.   6.18 LIFE SCIENCES, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion)
  164.   6.19 LIFE SCIENCES, BY AGE GROUP, 2024 (% SHARE)
  165.   6.20 LIFE SCIENCES, BY AGE GROUP, 2024 TO 2035 (USD Billion)
  166.   6.21 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  167.   6.22 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
  168.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  169. 7 LIST OF TABLES
  170.   7.1 LIST OF ASSUMPTIONS
  171.     7.1.1
  172.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  173.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  174.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  175.     7.2.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  176.     7.2.4 BY AGE GROUP, 2025-2035 (USD Billion)
  177.     7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  178.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  179.     7.3.1
  180.   7.4 ACQUISITION/PARTNERSHIP
  181.     7.4.1

US Life Sciences Market Segmentation

Life Sciences By Type (USD Billion, 2025-2035)

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid

Life Sciences By Route of Administration (USD Billion, 2025-2035)

  • Parenteral
  • Oral

Life Sciences By Disease Indication (USD Billion, 2025-2035)

  • Viral Diseases
  • Bacterial Diseases

Life Sciences By Age Group (USD Billion, 2025-2035)

  • Pediatric
  • Adults

Life Sciences By Distribution Channel (USD Billion, 2025-2035)

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓